- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07938164
ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares (ACUTE-GO)
A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares
The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.
Researchers will compare two different doses of Purified Cortrophin Gel.
Participants will:
- Receive one injection of Purified Cortrophin Gel
- Have 2 in-person visits to the site and 3 virtual/telephone visits
- Complete daily surveys about their gout flare
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Ashley Gantt
- Numéro de téléphone: 678-527-1332
- E-mail: ashley.gantt@anipharmaceuticals.com
Lieux d'étude
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02114
- Recrutement
- Mass General Hospital
-
Chercheur principal:
- Hyon K Choi, MD, DrPH
-
Contact:
- Ana D Fernandes, MA
- Numéro de téléphone: 617-643-2140
- E-mail: adfernandes@mgh.harvard.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Main inclusion criteria:
-
Signed informed consent to participate in this study.
-
Male and female patients, aged 18-90 years.
-
Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.
-
Onset of current acute gout flare within 5 days prior to study entry
-
Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).
-
History of ≥ 1 gout flares within the 12 months prior to study entry
-
The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:
- Minimum of one episode of inadequate response to treatment.
- The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
-
Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.
Main exclusion criteria:
-
Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.
-
Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).
-
Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.
-
Patients with sensitivity to proteins derived from porcine sources.
-
Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
-
Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.
-
Polyarticular gouty arthritis flare currently active in more than 4 joints.
-
Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.
-
Previous inclusion in this study.
-
Patients currently receiving dialysis.
-
Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
-
Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
-
Prior or current treatment with any ACTH product.
-
Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.
- Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
- Acceptable methods of contraception are:
i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)
-
Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
-
Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.
-
Vaccination within 30 days prior to study enrollment and during the study period.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: 40 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 40 U |
|
Comparateur actif: 80 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 80 U |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following PCG administration.
Délai: From baseline to Day 3
|
Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
From baseline to Day 3
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)
Délai: Baseline to Day 1
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 |
Baseline to Day 1
|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)
Délai: Baseline to Day 2
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
Baseline to Day 2
|
|
Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection
Délai: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to onset of effect (≥20% change from baseline pain intensity on VAS)
Délai: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to response (≥50% change from baseline pain intensity on VAS)
Délai: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)
Délai: Baseline to Day 7
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 7
|
|
Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)
Délai: Baseline to Day 3
|
Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3): Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome. Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome. Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome. Erythema - categorical assessment: present, absent, or not assessable. |
Baseline to Day 3
|
|
Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)
Délai: Baseline to Day 3
|
Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug. |
Baseline to Day 3
|
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)
Délai: Baseline to Day 3
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 3
|
|
Use of rescue medication (up to 72-hours post-injection)
Délai: Baseline to Day 3
|
Baseline to Day 3
|
|
|
Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)
Délai: Baseline to Day 7
|
Safety will be assessed as follows: Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug). Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable). Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period. |
Baseline to Day 7
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change from Baseline in Serum C-Reactive Protein (CRP) Level
Délai: Baseline to Day 3
|
Levels of C-reactive protein inflammatory markers (baseline [Day 0], 72 hours [Day 3]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation |
Baseline to Day 3
|
|
Change from Baseline in Gout Attack Intensity Score (GAIS)
Délai: Baseline to Day 3
|
Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity. |
Baseline to Day 3
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Arthropathies cristallines
- Maladies musculo-squelettiques
- Arthrite
- Maladies articulaires
- Maladies rhumatismales
- Métabolisme de la purine-pyrimidine, erreurs innées
- Métabolisme, erreurs innées
- Maladies génétiques, innées
- Maladies métaboliques
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies nutritionnelles et métaboliques
- Goutte
Autres numéros d'identification d'étude
- ANI-PCG-003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .